



Final Program

ANZHNCS ASM 2022

Australian and New Zealand Head & Neck Cancer
Society 23rd Annual Scientific Meeting

26 - 28 August 2022

Gold Coast Convention and Exhibition Centre
Gold Coast, Australia

*Evolving Paradigms in
Head and Neck Cancer:*
Escalation, De-escalation
and Everything in Between



AUSTRALIAN AND NEW ZEALAND
**HEAD & NECK
CANCER SOCIETY**



www.anzhnccs.org

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Welcome

It is with great honour and pleasure that I welcome you to the ANZHNCS ASM 2022 on the Gold Coast.

The Organising Committee have put together a program reflecting the theme; 'Evolving Paradigms in Head and Neck Cancer: Escalation, De-escalation and Everything in Between'.

We are excited to have a diverse and engaging group of international speakers who will deliver keynote talks on the latest research and clinical advances. Colleagues from the local Australia and New Zealand faculty will ably support our international guests throughout the meeting with the format including; keynote presentations, multidisciplinary tumour boards, debates and a breakfast session with a twist.

We would also like to take this opportunity to acknowledge and thank our Gold Sponsor; Sanofi Australia, Silver Sponsors; Medtronic and Varian, and our Bronze Sponsors; Atos Medical, Bayer, Bristol-Myers Squibb, KLS Martin Australia, Lyka Smith, MSD, QML Pathology and Stryker along with the companies participating in the industry exhibition. Your continued support is greatly valued.

It has been an incredibly difficult period of time over the last couple of years with the shape-shifting virtual nature of these conferences, so again we look forward to spending some in-person time with colleagues.

We are grateful for your attendance and hope you enjoy the beautiful weather that the Gold Coast has to offer.



Dr Sam Dowthwaite
ANZHNCS ASM 2022
Convener

Keynote Speakers



Professor Ehab Hanna
Houston, USA

Professor and Vice Chair of the Department of Head and Neck Surgery with a joint appointment in the Department of Neurosurgery. Adjunct Professor of Otolaryngology, Otorhinolaryngology and Communicative Sciences, Head and Neck Surgery at Baylor College of Medicine.



Dr Justin Roe
London, UK

Consultant and Professional Lead for Speech and Language Therapy at the Royal Marsden NHS Foundation Trust in London. Clinical Service Lead at the National Centre for Airway Reconstruction/Laryngology Service at Imperial College Healthcare NHS Trust. Honorary Clinical Senior Lecturer in the Department of Surgery and Cancer at Imperial College London.



Professor Sue Yom
San Francisco, USA

Vice Chair of Strategic Advisory and the Irwin Mark Jacobs and Joan Klein Jacobs Distinguished Professor in the Departments of Radiation Oncology and Otolaryngology - Head and Neck Surgery at the University of California, San Francisco.



Professor John Yoo
London, Canada

Dean of the Schulich School of Medicine & Dentistry at Western University. President of the Canadian Association of Head and Neck Surgical Oncology.

2022 ANZHNCS Chris O'Brien Orator



Professor Ben Panizza
Brisbane

Director of Otolaryngology - Head and Neck Surgery at Princess Alexandra Hospital in Brisbane, Australia and Chair of ENT Services for Metro South Health.

For full speaker biographies please visit the meeting app.



ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Organising Committee

Convener

Dr Sam Dowthwaite | ENT/Head and Neck Surgeon, Gold Coast University Hospital, Gold Coast

Organising Committee Members

Associate Professor Jim Jackson | Radiation Oncologist, Gold Coast University Hospital, Gold Coast

Dr Matthew Cronin | ENT/Head and Neck Surgeon, Gold Coast University Hospital, Gold Coast

Dr Marcin Dzienis | Medical Oncologist, Gold Coast University Hospital, Gold Coast

Ms Penny Stabler | Speech Pathologist, Gold Coast University Hospital, Gold Coast

Members of the ANZHNCS Executive Committee

President:	Dr Tsien Fua Radiation Oncologist
Vice President:	Dr Eng Hooi Ooi Otolaryngology Head & Neck Surgeon
Treasurer:	Dr Julia Crawford Otolaryngologist Head & Neck Surgeon
Secretary:	Dr Thasvir Singh Oral Maxillofacial Surgeon
Immediate Past President:	Dr Brian Stein Medical Oncologist
Australian Research Foundation Chair:	Dr Kerwin Shannon General Surgeon
New Zealand Research Foundation Chair:	Dr Swee Tan (ENT) Plastic & Reconstructive Surgeon
Executive:	Dr Robert Coren Plastic & Reconstructive Surgeon Dr Camile Farah Oral Medicine Specialist Dr Eric Khoo Radiation Oncologist Dr Aoife McGarvey Physiotherapist Dr Felix Sim Oral Maxillofacial Surgeon
Non-Member Executive:	Rod Wellington Glen Ramos

Australian and New Zealand Head & Neck Cancer Society (ANZHNCS)

Early in 1998, a number of head and neck oncologists from the disciplines of surgery, radiation oncology and medical oncology met in Sydney to discuss the feasibility of establishing a multidisciplinary head and neck cancer society. A working party was formed and following a number of meetings, invitations were sent to individuals in these three specialties to become foundation members of the Australian and New Zealand Head & Neck Cancer Society.

The initial business meeting was held on December 9, 1998 and at that time there were 60 foundation members. The Society adopted as its Constitution the Model Rules for Associations published by the Department of Fair Trading in NSW and the members agreed that their principal objectives would be to promote the practice of head and neck oncology, to educate medical colleagues and the public about our specialty, to foster research and to seek optimal treatment outcomes for our patients.

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Sponsors and Exhibitors

(correct at time of printing)

Sponsors

Gold Sponsor

sanofi

Silver Sponsors

Medtronic

varian

A Siemens Healthineers Company

Bronze
Sponsors

Atos
Breathing-Speaking-Living



Bristol Myers Squibb™

KLS martin
GROUP

LYKA SMITH
Australian Innovation

MSD

QML Pathology

stryker

Educational
Sponsor

**Royal Australasian
College of Surgeons**

Name Badge &
Lanyards Sponsor

Qscan
RADIOLOGY CLINICS

Meeting Dinner
Sponsor

ICON
CANCER CENTRE

Breakfast Session
Sponsor

**DEVICE
TECHNOLOGIES**

Exhibitors

AMBU AUSTRALIA
ANZHNCS & HANCA

Atos Medical

Bayer

Genesis Care

Gold Coast Hospital Foundation

KLS Martin Australia

Lateral Medical

LYKA SMITH

MAIN MEDICAL

Medtronic

MSD

OPTISCAN IMAGING LTD.

QML PATHOLOGY

Sanofi Australia

South Coast Radiology

Stryker

Varian

ZEISS

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

General Information

Date and Venue

The ANZHNCS ASM 2022 will be held at the Gold Coast Convention and Exhibition Centre (GCCEC) from Friday 26 August to Sunday 28 August 2022. For further information please visit gccec.com.au.

Registration Desk

The registration desk will be located in Room Foyer on Level 1, GCCEC and will be open during the following hours:

Friday 26 August 2022: 7:00am – 5:00pm

Saturday 27 August 2022: 7:00am – 5:00pm

Sunday 28 August 2022: 7:30am – 10:30am

Registration Information

Full registration includes:

- Access to all scientific sessions
- Access to the industry exhibition
- Morning and afternoon tea refreshments in accordance with the program
- Lunch in accordance with the program
- Welcome Reception Ticket (Friday 26 August 2022)*

**The Welcome Reception is not included in day registration categories. Tickets must be purchased separately for the Welcome Reception.*

One day registration includes:

- Access to all scientific sessions (as applicable)
- Access to the industry exhibition
- Morning and afternoon tea refreshments in accordance with the program
- Lunch in accordance with the program

Concessional Registration

Concessional registration is available to nurses, allied health professionals, trainees and medical students.

Industry Representatives Registrations

Registration is open to representatives from companies participating in the industry exhibition only. Representatives must register as a company representative and not a delegate. Registrations from representatives of non-participating companies will not be accepted in any form.

Parking

The Gold Coast Convention and Exhibition Centre (GCCEC) operates an automated car parking system. The cost is \$12.00* per vehicle per entry, payable upon exiting the Centre. There are pay stations positioned throughout various locations in the Centre.

As the GCCEC is a cashless venue, these machines will only accept card transactions. A 30-minute complimentary period applies to all vehicles. Should this period be exceeded, a \$12 fee will apply.

**Pricing correct at time of release. Please refer to the Gold Coast Convention and Exhibition Centre's website for the most up to date information.*

Certificate of Attendance

A certificate of attendance will be circulated electronically after the meeting.

**LYKA SMITH**
Australian Innovation



Custom Reconstruction Solutions

- Australian made
- Virtual planning with local engineers
- 3-5 Day turnaround
- Customised patient specific cutting, drilling and fixation guides and plates
- Fibula free flap, scapular reconstruction and combined dental implant planning

1B/40-52 McArthurs Rd, Altona North VIC 3025 www.lykasmith.com

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

General Information (cont'd)

Continuing Medical Education (CME)/ Continuing Professional Development (CPD) Points

This educational activity has been approved in the RACS CPD Program. RACS Fellows, Specialist International Medical Graduates (SIMGs) and surgeons participating in the RACS CPD Program can claim one point per hour in Educational Activities (maximum 17 points).

RACS Fellows, participation in this activity will be entered into your RACS CPD which can be accessed through ehub if you provided your RACS ID when registering.

Intention to Photograph

Please be advised that photographs may be taken during the meeting and reproduced by the meeting organiser.

These photos may be used for the following purposes:

- Projection onsite
- Reporting on the meeting online
- Marketing a future meeting, including online and hard copy publications
- Publishing in RACS/ANZHNCS publications

If you do not wish to be included in a photograph, please advise the photographer.

Awards

Best Overall Oral Presentation - Amount \$500.00

Best Overall Poster Presentation - Amount \$500.00

The above-mentioned prizes will be awarded at the meeting. Entries are assessed during the meeting and then announced at the close of the meeting.

Industry Exhibition

The industry exhibition will be held in Central Rooms A, B and C, Ground Floor, Gold Coast Convention and Exhibition Centre. Delegates will have the opportunity to visit industry booths and view the posters in the program breaks.

Posters

Posters will be displayed in the industry exhibition and will be available for viewing throughout the meeting.

Speakers' Support

Presenters are required to provide an electronic PowerPoint copy of their presentation to the Speakers Support desk at the meeting at least one hour prior to the commencement of their session. Speakers' Support is located at the back of the room in Rooms 5 & 6, First Floor, Gold Coast Convention and Exhibition Centre. A technician will be available at the Speakers' Support desk one hour prior to the commencement of the first session and during the catering breaks from Friday 26 August to Sunday 28 August 2022.



We use the power of
leading-edge science
to save and improve
lives

For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

 **MSD**
INVENTING FOR LIFE

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited, Level 1 - Building A, 26 Talavera Road, Macquarie Park NSW 2113. AU-NON-00577. First issued July 2022.

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

General Information (cont'd)

Dietary Requirements

Please note that the venue is responsible for all catering at the meeting and ANZHNCS/RACS does not inspect or control food preparation areas or attempt to monitor ingredients used. You should contact the venue directly for all special dietary requirements during the event, irrespective of whether details have been provided to ANZHNCS/RACS. If ANZHNCS/RACS requests information about your dietary requirements for a specific event ANZHNCS/RACS will endeavour to forward the information provided to the venue (time permitting). ANZHNCS/RACS will not retain information provided for future events, so you must verify your requirements for each event. Even if information is requested or provided, ANZHNCS/RACS takes no responsibility for ensuring that the venue acknowledges your dietary requirements or that these requirements can be met. In all cases you must verify for yourself that your dietary requirements have been met and ANZHNCS/RACS refutes any and all liability for any failure to adequately provide your special dietary requirements or any consequential damage resulting from such failure.

Business Meetings

ANZHNCS Executive Committee Meeting (Executive Committee Members only)

Date: Thursday 25 August 2022

Time: 5:00pm - 6:30pm

Venue: Room 4, First Floor, Gold Coast Convention and Exhibition Centre


ANZHNCS Annual General Meeting (AGM) (ANZHNCS Members only)

Date: Saturday 27 August 2022

Time: 12:00pm - 1:00pm

Venue: Rooms 5 & 6, First Floor, Gold Coast Convention and Exhibition Centre

The more efficient, flexible, personal & intelligent way to outsmart cancer.



With Ethos™ therapy, you can adapt treatment plans daily while transforming your cancer fight completely.

Ethos therapy is our AI-driven holistic solution that lets you choose the most appropriate treatment option based on daily changes in patient anatomy. It also delivers an entire adaptive treatment in a typical 15-minute timeslot, from setup through delivery. Redefine how you fight cancer — experience Ethos therapy at varian.com/ethos today.

Safety Information: Radiation may cause side effects and may not be appropriate for all cancers.

© 2022 Varian Medical Systems, Inc. Varian is a registered trademark of Varian Medical Systems, Inc.

Refer enquiries to Varian Medical Systems Australasia on 1800.657.036 or customerservice-anz@varian.com

varian
A Siemens Healthineers Company

ETHOS™

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Official Functions

Welcome Reception

Friday 26 August 2022, 5:00pm – 7:00pm

Central Rooms A, B and C, Ground Floor, Gold
Coast Convention and Exhibition Centre, Gold Coast

Cost: Included for full registration categories*,
bookings essential

Dress: Business attire or smart casual

**Subject to availability at the time of booking*

Additional tickets: \$65.00 per person

Network with the academic faculty, industry and
fellow colleagues whilst celebrating the opening of
this important meeting.

Meeting Dinner

Saturday 27 August 2022, 6:30pm – 11:00pm

Foyer E, First Floor, Gold Coast Convention and
Exhibition Centre, Gold Coast

Cost: Meeting Dinner Ticket (All-inclusive)* |
\$150.00

Meeting Dinner Ticket (Excluding alcohol)* |
\$130.00

Dress: Lounge suit/cocktail with a touch of the
tropics (think florals, colour and beachy)

**Subject to availability at the time of booking*

Please arrive at 6:30pm in Foyer F, First Floor for
pre-dinner canapes, followed by a delightful three-
course dinner and entertainment with colleagues
and friends.

*If you would like to attend any of the official functions,
please visit the team at the registration desk. Please
note that the meeting dinner is not included in the
registration fee.*

Inaugural ANZHNCS 'Triathlon'

The organising committee is extending an invitation
to all registered delegates to attend the inaugural
ANZHNCS "Triathlon".

Details can be found below:

Saturday 27 August 2022, 6:00am - 7:00am

Meeting Point: Please meet at Kurrawa Surf Club,
Old Burleigh Road, Broadbeach, Queensland.

We will have some world class athletes and
professional coaches present to help guide you
through a fun movement-based morning. Choose
one activity, either:



*In the
water*




*Bike
ride*



*Jog along Gold
Coast's beaches*

*No registration is required and all fitness levels are
welcome.*

KLS martin
GROUP



Be connected to a global network of IPS® planning, design and
manufacturing sites via our local team of experienced, qualified
Biomedical Engineers.

IPS Implants®
Individual Patient Solutions.



ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*


26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

DOWNLOAD THE MEETING APP

The full scientific program is available on the meeting app. To download the app please follow the steps below:

1. Search 'The Event App by EventsAir' in the Google Play or Apple App store.
2. Once downloaded, enter the event code 'anzhnscs22' to access the ANZHNCS 2022 meeting app, including speaker information, abstracts and programs etc.



EVIDENCE THAT EMPOWERS CHANGE

Empowered decision-making for
your patients with advanced CSCC

For patients with advanced cutaneous squamous cell carcinoma (CSCC).¹

LIBTAYO demonstrated clinically meaningful responses^{1*}

- **49.2% ORR** (95% CI, 35.9%-62.5%) for Group 1[†] (**mCSCC**)
- **43.6% ORR** (95% CI, 32.4%-55.3%) for Group 2[†] (**laCSCC**)
- **41.1% ORR** (95% CI, 28.1%-55.0%) for Group 3[†] (**mCSCC**)

LIBTAYO demonstrated durable responses^{1‡}

- Median duration of response was not reached in any group
- The estimated proportion of patients with ongoing response ≥6 months: 93.1% for Group 1, 67.6% for Group 2, and 65.2% for Group 3

Demonstrated risk/benefit profile with LIBTAYO¹

- Adverse events were serious in 30.0% of patients. Adverse events led to permanent discontinuation of LIBTAYO in 7.5% of patients¹
- irARs occurred in 20.1% of patients treated with LIBTAYO¹
- The most common irARs were hypothyroidism (6.9%), pneumonitis (3.0%), hyperthyroidism (2.9%), hepatitis (1.9%), colitis (1.8%) and immune-related skin adverse reactions (1.8%)¹

PROVISIONALLY REGISTERED

IN ADVANCED CSCC

LIBTAYO as monotherapy has **provisional approval** in Australia for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.¹

The decision to approve this indication has been made on the basis of objective response rate (ORR) and duration of response from single arm clinical studies. The sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.¹

▼ This medicinal product is subject to additional monitoring in Australia due to provisional approval. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

PBS Information: This product is not listed on the PBS

Study 1540 was a phase 2, pivotal, open-label, multicentre study that enrolled 193 patients with mCSCC or laCSCC, with a combined median follow-up of 9.4 months. Treatment may be continued until disease progression, unacceptable toxicity, or completion of planned treatment. The primary endpoint was confirmed ORR as assessed by ICR. Secondary endpoints included DOR, PFS, OS, and CR rate.¹

LIBTAYO demonstrated an acceptable risk/benefit profile in clinical studies of 1,078 patients with advanced solid malignancies including 219 advanced CSCC patients who received LIBTAYO monotherapy.¹ The recommended dose is 350 mg of LIBTAYO every 3 weeks (Q3W) administered as an intravenous infusion over 30 minutes. Treatment may be continued until disease progression or unacceptable toxicity.¹

*Data cutoff was 20 September 2018 for Groups 1 and 3 and 10 October 2018 for Group 2.¹

[†]In Groups 1, 2, and 3, median durations of follow-up were 16.5 months, 9.3 months, and 8.1 months, respectively.¹

[‡]Based on Kaplan-Meier estimates.¹

CR=complete response; CSCC=cutaneous squamous cell carcinoma; DOR=duration of response; ICR=independent review committee; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.

Reference: 1. LIBTAYO® (cemiplimab) Approved Product Information. December 2021.

Please review full Product Information before prescribing. Full Product Information is available at www.guillink.com.au/gc/ws/sw/pi.cfm?product=swplibta or by contacting Sanofi Medical Information on 1800 818 806.

sanofi

Sanofi and Regeneron are collaborating in the global development and commercialisation for LIBTAYO® (cemiplimab).

©2022 Sanofi-Aventis Australia Pty Ltd trading as Sanofi. All rights reserved.

Sanofi-Aventis Australia Pty Ltd trading as Sanofi ABN 31 008 558 807. Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113, AUSTRALIA. www.sanofi.com.au

Date of preparation: July 2022. MAT-AU-2102060 (v1.1)

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (correct at time of printing)

Friday 26 August 2022

8:00am - 10:00am **Opening/Plenary Session 1** **Rooms 5 & 6**

**Chairs: Dr Sam Dowthwaite &
Dr Tsien Fua**

Proudly sponsored by: **sanofi**

8:00am Meeting Welcome /
Acknowledgement of Country
Dr Sam Dowthwaite

8:10am ANZHNCS Research Foundation
Dr Kerwin Shannon

8:20am Introduction to Chris O'Brien
Oration
Dr Jim Hallam

8:25am Chris O'Brien Oration
Professor Ben Panizza

8:55am Keynote Lecture: Value Based
Health Care Delivery in Head and
Neck Cancer
Professor Ehab Hanna

9:25am Keynote Lecture: Role of the
Scapula in Head and Neck
Reconstruction
Professor John Yoo

10:00am - 10:30am **Morning tea with the industry** **Central Rooms A, B & C**

10:30am - 12:00pm **Concurrent Session 2A - Functional Futures** **Room 7** **Chairs: Dr Clare Burns & Ms Penny Stabler**

10:30am Impacts to post-laryngectomy
pulmonary health following
adoption of an optimal Day-and-
Night regimen using new
generation Heat and Moisture
Exchangers (HMEs)
Professor Elizabeth Ward

10:45am Exploring dyadic management of
nutrition care throughout and
beyond head and neck cancer
treatment
Ms Joanne Hiatt

11:00am

Making emergency laryngectomy
training SIM-ulating: A novel
approach to Speech Pathology
staff education

Ms Anita Macdonald-D'Silva

11:15am

Establishing a Fibreoptic
Endoscopic Evaluation of Swallow
(FEES) screening protocol to
support detection of late-stage
dysphagia post radiation therapy
for head and neck cancer

Mrs Rachelle Robinson

11:30am

The feasibility of skeletal muscle
assessment at the second thoracic
vertebral level for CT-defined
sarcopenia in patients with head
and neck cancer

Miss Belinda Vangelov

stryker

Facial iD™


3D Printed patient specific plating



Orthognathics



**Midface and
mandible trauma**



Midface reconstruction

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) (correct at time of printing)

11:45am	Who, what, when and how? Benchmark of SLP rehabilitation following oral cancer <i>Dr Katrina Blyth</i>	1:00pm - 2:30pm	Concurrent Session 3A - Reconstruction Rooms 5 & 6 Chairs: Dr Andrew Foreman & Dr Tsu-hui (Hubert) Low
10:30am - 12:00pm	Concurrent Session 2B - Robotics Rooms 5 & 6 Chairs: Dr Julia Crawford & Dr Ben Dixon	1:00pm	Free flap morbidity - what would you know doc, you've never had one <i>Associate Professor Martin Batstone</i>
10:30am	Can imaging findings predict HPV status: Imaging of oropharyngeal SCCs and TORS <i>Professor Sandeep Bhuta</i>	1:20pm	Reconstructive Strategies in Tumour involving the Facial Nerve <i>Associate Professor Tsu-hui (Hubert) Low</i>
10:45am	Rationalisation of adjuvant radiation therapy in good prognosis HPV OPC treated with trans oral surgery (TOS) <i>Professor June Corry</i>	1:35pm	Long-term health-related quality of life and functional outcomes after reconstructive surgery of the maxilla and mandible: a cross-sectional study <i>Dr Rebecca Venchiarutti</i>
11:00am	Vascular control in transoral robotic surgery <i>Associate Professor Richard Gallagher</i>	1:50pm	Timing of ansa cervicalis-to- recurrent laryngeal nerve reinnervation: a systematic review <i>Dr Matthew Fadhil</i>
11:15am	Nutritional outcomes in patients undergoing transoral robotic surgery for head and neck cancers compared to conventional open surgery. A systematic review <i>Dr Teresa Brown</i>	2:00pm	Innervated composite free flaps for total lip reconstruction: the Royal Brisbane and Women's Hospital experience <i>Dr Daniel Lake</i>
11:30am	Staged neck dissection prior to Transoral Robotic Surgery for oropharyngeal cancer - does it reduce post-operative complication rates? A multi-centre study of 91 patients <i>Dr Anne Tescher</i>	2:10pm	A Novel Paradigm for Nasal Reconstruction <i>Associate Professor Sydney Ch'ng</i>
		2:20pm	Peripheral nerve repair with olfactory ensheathing cell nerve bridges; a potential for head and neck reconstruction <i>Dr Stephen Crouch</i>
11:45am	Evolution of robotic platforms for TORS <i>Dr Peter Floros</i>	1:00pm - 2:30pm	Concurrent Session 3B - Equity & Resource Management Room 7 Chairs: Associate Professor Roger Grigg & Dr Nicole Buddle
12:00pm - 1:00pm	Lunch with the industry Central Rooms A, B & C	1:00pm	Integrated speech pathology telepractice service for swallowing rehabilitation: A feasibility study <i>Dr Clare Burns</i>

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) (correct at time of printing)

1:15pm	Mapping differences by rurality in the healthcare needs, access and experience of post-acute recovery in people with head and neck cancer <i>Mrs Jasmine Foley</i>
1:30pm	A retrospective analysis of microvascular reconstruction at a New Zealand Oral and Maxillofacial Surgical Unit <i>Dr Ellen Simpson</i>
1:45pm	Ethnic disparities for survival and mortality rates in patients with Head and Neck cancers: A retrospective study of New Zealand's Oncology patients over ten years <i>Dr Abigail Weaver</i>
2:00pm	Creating an algorithm for treatment of head and neck squamous cell carcinoma of unknown primary <i>Dr Megan Blom</i>
2:10pm	What are we doing? Benchmark of speech outcomes used by SLPs following oral cancer <i>Dr Katrina Blyth</i>
2:20pm	Latest news from Head and Neck Cancer Australia <i>Nadia Rosin, CEO Head and Neck Cancer Australia</i>
2:30pm - 3:00pm	Afternoon tea with the industry Central Rooms A, B & C
3:00pm - 5:00pm	Plenary Session 4 Rooms 5 & 6 Chairs: Associate Professor Jim Jackson & Professor Elizabeth Ward
3:00pm	Keynote Lecture: Nasopharyngeal Carcinoma in 2022: A Rapidly Shifting Landscape <i>Professor Sue Yom</i>

3:30pm	Keynote Lecture: From Parotid Sparing to Swallow Sparing Radiation Therapy - How Are We Doing? <i>Dr Justin Roe</i>
4:00pm	Patient selection for and the relative quality of life impact of transoral robotic surgery for HPV+ oropharynx carcinoma <i>Dr William Ryan</i>
4:30pm	Debate 1: Regional versus Metropolitan Cancer Care Services <i>Moderator: Dr Scott Coman</i> <i>Panel: Associate Professor Roger Grigg, Dr Nicole Buddle, Dr Ryan Adams, Dr Matthew Cronin, Dr Catherine Barnett & Dr Rahul Ladwa</i>

5:00pm - 7:00pm	Welcome Reception & Quick Fire Presentations Central Rooms A, B & C <i>Facilitators: Dr Sam Dowthwaite & Dr Marcin Dzienis</i> An alternative free myocutaneous reconstruction for a total lower lip defect: A case report <i>Dr Tasciana Gordon</i> Development of a Patient Reported Outcome Measure (PROM) for Midface Cancer Surgery Patients <i>Dr Jason Luong</i> Building team performance in head and neck surgery; lessons learned from plane crashes <i>Dr Milap Rughani</i> Implication of oesophageal dysmotility in post-laryngectomy dysphagia and voice dysfunction <i>Dr Veena Wadhwa</i> <i>All quick fire presenters will have 5 minutes to present their poster and answer any questions from the facilitators.</i>
-----------------	---

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) (correct at time of printing)

Saturday 27 August 2022

7:30am - 9:00am	Breakfast Session 5 - OPSCC De-escalation Update Room 7 Chairs: Dr Sam Dowthwaite & Professor Suren Krishnan <i>Proudly sponsored by:  DEVICE TECHNOLOGIES</i>	10:50am
7:30am	ORATOR trials <i>Dr Anthony Nichols & Dr David Palma</i>	11:10am
7:50am	NRG Trials <i>Professor Sue Yom</i>	11:25am
8:10am	PATHOS trial <i>Professor Joanne Patterson</i>	11:40am
8:30am	Cases with the experts <i>Facilitators: Dr Sam Dowthwaite & Professor Suren Krishnan</i> <i>Experts: Dr Anthony Nichols, Dr David Palma, Professor Sue Yom & Professor Joanne Patterson</i>	
9:00am - 10:00am	Plenary Session 6 Rooms 5 & 6 Chair: Dr Marcin Dzienis & Dr Penny Mackenzie	
9:00am	Changing trends in mucosal head and neck cancer - A statewide (Queensland) analysis <i>Professor Sandro Porceddu</i>	
9:30am	Keynote Lecture: De- intensification of Therapy in HPV- Associated Oropharyngeal Carcinoma: Is there an End Game? <i>Professor Sue Yom</i>	
10:00am - 10:30am	Morning tea with the industry Central Rooms A, B & C	
10:30am - 12:00pm	Concurrent Session 7A - Skull Base Rooms 5 & 6 Chairs: Dr Ryan Sommerville & Dr Eric Khoo	
10:30am	Evolution of perineural malignancy management and use of MRI in the skull base <i>Dr Ryan Sommerville</i>	

Imaging of Sinonasal Cancers:
Multidisciplinary Approach and
Surgical Implications
Professor Sandeep Bhuta


Osseointegrated implant
treatment outcomes for
craniofacial resection in a large
multi-centre cohort: the impact of
postoperative radiotherapy and
smoking
Dr Domagoj Vodanovich

Approach to Tumors of the
Anterior Nasal Cavity
Dr Amanda Yung

Reconstruction of anterior skull
base defects with anterolateral
thigh musculo-fascial free flap - A
case series
Dr Cameron Harrison

Did you know that
immediate Post-Op
HME therapy following
Total Laryngectomy can
significantly reduce
pulmonary complaints
and is associated with
lower health care costs.

**PROVOX[®]
Life**



info.au@atosmedical.com

Atos
Imaging - Speaking - Living

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) (correct at time of printing)

11:50am	Persisting facial nerve palsy or trigeminal neuralgia – red flags for perineural spread of Head and Neck Cutaneous Squamous Cell Carcinoma (HNCSCC) <i>Dr Michael Zhang</i>	1:15pm	Swallowing outcomes post chemoradiotherapy for low-risk human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma <i>Dr Rhys Hughes</i>
10:30am - 12:00pm	Concurrent Session 7B - The Patient First Room 7 Chairs: Mrs Rachelle Robinson & Ms Karen Whitelock	1:25pm	Survival and toxicity with reduced dose radiotherapy for human papillomavirus associated oropharyngeal squamous cell carcinoma – a systematic review and meta-analysis <i>Dr Timothy Lee</i>
10:30am	Evaluation of normative datasets for reporting quality of life and symptoms following head and neck cancer treatment <i>Dr Ashlee Kimball</i>	1:40pm	FDG PET CT utilisation in head and neck cancer: Our experience <i>Dr Anita McNamee</i>
10:45am	Physiotherapy provision for head and neck cancer survivors: A mixed methods study of knowledge translation <i>Dr Aoife McGarvey</i>	1:50pm	Sexual health in head and neck cancer survivors <i>Dr Lachlan McDowell</i>
11:00am	Facial Prosthetic Rehabilitation Following Head and Neck Cancer <i>Ms Sophie Fleming</i>	2:05pm	The SUROC - Long-term Survivorship based tool to direct treatment decisions for Oropharyngeal Cancers <i>Dr Arjun Singh</i>
11:30am	Patient interview - Mr Kenton Campbell and Mr Manuel Carracedo <i>Dr Heather Green</i>	2:15pm	The utility of salivary Human Papillomavirus as a sentinel marker for recurrent/residual disease following the treatment of oropharyngeal cancer <i>Dr Zhen Yu Liu</i>
12:00pm - 1:00pm	Lunch with the industry Central Rooms A, B & C	1:00pm - 2:30pm	Concurrent Session 8B - Foundational Sciences Room 7 Chairs: Professor Sandeep Bhuta & Professor Newell Johnson
12:00pm - 1:00pm	ANZHNCS AGM Rooms 5 & 6		
1:00pm - 2:30pm	Concurrent Session 8A - The Oropharynx Rooms 5 & 6 Chairs: Associate Professor Charles Lin & Dr Matthew Magarey	1:00pm	Driver or passenger: Instigator or healer. The role of the microbiome in oral carcinogenesis <i>Professor Newell Johnson</i>
1:00pm	Oropharynx squamous cell carcinoma – a disease in evaluation <i>Professor Robert Smee</i>	1:20pm	HN Cancers with SPECTRAL CT: Imaging Trends and New Horizons <i>Professor Sandeep Bhuta</i>
		1:35pm	Mucosal head and neck squamous cell carcinoma: The role of the tumour microenvironment in pathogenesis and its influence on anti programmed-death-1 therapies <i>Dr Thomas Beddow</i>

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) (correct at time of printing)

- 1:50pm Gold nanoparticles against oropharyngeal pathogens in cancer therapy
Dr Minati Choudhury
- 2:00pm Tissue resident memory T cells in head and neck cancer
Dr Alesha Thai
- 2:10pm A step toward real-time histological screening of oral lesions: A confocal laser endomicroscopic approach
Dr Sneha Sethi
- 2:20pm Pilot study to evaluate perioperative high dose rate brachytherapy in locally advanced head and neck cancers
Dr Amit Bahl
- 2:30pm - 3:00pm **Afternoon tea with the industry**
Central Rooms A, B & C
- 3:00pm - 5:00pm **Plenary Session 9**
Rooms 5 & 6
Chairs: Dr Matthew Cronin & Dr Catherine Barnett
- 3:00pm Keynote Lecture: Functional outcomes for people undergoing reconstructive surgery for oral cancer and osteoradionecrosis utilising an early, post-operative feeding approach
Dr Justin Roe
- 3:30pm Multidisciplinary Tumour Board - Contemporary Salvage Treatment of Recurrent Head and Neck Cancer
Panel: Dr Julianne Agnew, Dr Ben Wallwork, Dr Julia Crawford, Dr Aaron Hansen, Dr Justin Roe, Dr Lachlan McDowell
- 4:15pm Debate 2: "Choose Your Weapon!" Surgery versus Non-surgery in the Management of Head and Neck Cancer
Moderator: Professor Bill Coman
Panel: Professor Sandro Porceddu, Professor Ben Panizza, Professor Jonathon Clark, Professor Sue Yom, Associate Professor Jim Jackson, Associate Professor Martin Batstone

6:30pm - 11:00pm **Meeting Dinner**

Foyer E

Proudly sponsored by: **ICON**
CANCER CENTRE

Sunday 28 August 2022

8:00am - 9:30am **Concurrent Session 10A - Slip, Slop, Slap**
Rooms 5 & 6

Chairs: Associate Professor Alex Guminski & Dr Sid Baxi

8:00am Clinical considerations for treating advanced squamous cell carcinoma of the scalp
Dr Tushar Agrawal

8:15am Recursive partitioning to determine order of significance of regional metastasis characteristics in head and neck cutaneous squamous cell carcinoma
Dr Michael Hurrell

OPDIVO
(nivolumab)



PBS listed for recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx

in patients who have progressed within 6 months of prior platinum-based chemotherapy^{1,2}

Refer to www.pbs.gov.au for full authority information.

Please refer to the Approved OPDIVO Product Information and Boxed Warning before prescribing. The full Product Information is available upon request from BMS Medical Information Department: 1800 067 567 or by scanning the QR code below.

OPDIVO
(nivolumab)

SCAN QR CODE to see full
OPDIVO Product Information



PBS = Pharmaceutical Benefits Scheme.

References: 1. Pharmaceutical Benefits Scheme (www.pbs.gov.au). 2. OPDIVO® (nivolumab) Approved Product Information.

© 2022 Bristol-Myers Squibb. OPDIVO® is a registered trademark of Bristol-Myers Squibb Company.
BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3170. 1506-AU-2200061. July 2022. BRMSCH1906.

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) (correct at time of printing)

8:30am	The role of the surgical margin for regional metastatic cutaneous disease in the head and neck region <i>Dr Timothy Manzie</i>	8:00am - 9:30am	Concurrent Session 10B - Oral & Salivary Room 7 Chairs: Dr Aaron Hansen & Dr Charles Giddings
8:45am	The use of FDG-PET in detecting lymph node metastases from scalp squamous cell carcinoma <i>Dr Emma McCabe</i>	8:00am	Surgery versus observation for parapharyngeal space tumours <i>Dr William Ryan</i>
9:00am	Surgical management of V1 perineural spread: outcomes and frontiers <i>Dr Lachlan Crawford</i>	8:20am	The latest in systemic therapy for recurrent metastatic salivary gland cancer <i>Dr Aaron Hansen</i>
9:15am	Imaging of cranial perineural spread <i>Dr Matthew Devine</i>	8:40am	A tumour-cell based initiation of immune evasion <i>Dr Rajdeep Chakraborty</i>
		8:55am	Failure in oral tongue squamous cell carcinoma <i>Dr James Daniell</i>

Medtronic

Engineering the extraordinary

NIM Vital™

Nerve Monitoring System

Designed to
protect all
that is vital



Medtronic Australasia Pty Ltd 2 Alma Road, Macquarie Park NSW 2113.
P: 02 9857 9000. www.medtronic.com.au
© 2022 Medtronic Australasia Pty Ltd. All Rights Reserved. ANZ10896-042022

ANZHNCS ASM 2022

*Evolving Paradigms in
Head and Neck Cancer*

26 - 28 August 2022

Gold Coast Convention and Exhibition
Centre Gold Coast, Australia

Final Program (cont'd) *(correct at time of printing)*

9:10am	Prognostic factors in carcinoma ex pleomorphic adenoma: systematic review Dr Seraphina Key	10:35am	Keynote Lecture: Neoadjuvant Therapy in the Management of Advanced Sinonasal and Skull Base Cancers Professor Ehab Hanna
9:20am	Sentinel lymph node biopsy for early oral cancer Dr Rajith Mendis	11:05am	Immunotherapy in HNSCC - the good, the bad and the not so ugly... Dr Aaron Hansen
9:30am - 10:00am	Morning tea with the industry Central Rooms A, B & C	11:35am	Multidisciplinary Tumour Board - Skull base challenges Panel: Professor Ben Panizza, Professor Ehab Hanna, Dr Ryan Sommerville, Dr James Bowman & Associate Professor Matthew Foote
10:00am - 12:00pm	Plenary Session 11 Rooms 5 & 6 Chairs: Dr Ben Chua & Dr Emily Guazzo	12:00pm	Presentation of awards and close of meeting Dr Sam Douthwaite
10:00am	ANZHNCS ASM 2023 Dr Aoife McGarvey		
10:05am	Keynote Lecture: Contemporary management of the paralyzed face Professor John Yoo		

FIND OUT MORE



**Visit us at the Bayer stand or
speak to your representative**

Bayer Australia Limited. ABN 22 000 138 714.
875 Pacific Highway, Pymble NSW 2073.
VIT050 | July 2022 | PP-VIT-AU-0048-1



QML Pathology

One of Australia's leading clinical
laboratory and pathology services.

- Based in Queensland for more than 90 years
- Offering a comprehensive service to doctors, private hospitals and aged care facilities throughout QLD and northern NSW
- Extensive, reliable and quality service with a vast spectrum of testing services and collection centres available
- Proudly part of the broader Healix Pathology network

qml.com.au

QML Pathology



#anzhnscasm23

SAVE THE DATE

10-12
August
2023

Crowne Plaza Hunter Valley,
Hunter Valley NSW, Australia

*Survivorship: When the
Complex Gets Complicated*

ANZHNC ASM 2023

*Australian and New Zealand Head & Neck
Cancer Society 24th Annual Scientific Meeting*



www.anzhncs.org



AUSTRALIAN AND NEW ZEALAND
HEAD & NECK
CANCER SOCIETY



ANZHNCS ASM 2022

26 - 28 August 2022

Gold Coast Convention and Exhibition Centre
Gold Coast, Australia

Meeting Organisers

Conferences & Events Management
Royal Australasian College of Surgeons
College of Surgeons Gardens
250 – 290 Spring Street
East Melbourne VIC 3002
Australia

T: +61 3 9249 1117

E: anzhncs.asm@surgeons.org